Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

In light of the variability in early ductal constriction and the early hemodynamic impact of an unconstricted DA, it may be that closure after the first 24 hours of life may be too late. Further, the ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

Twice as many preemies treated with drugs for patent ductus arteriosus died compared to those placed under observation Side effects of drug treatments might have unintended consequences for preemies, ...

Larger DA diameter was significantly related to this low systemic blood flow in the early hours after birth. [13] By the time the PDA became clinically apparent (mean 72 hours), the infants were ...